CN109999175A - 一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法 - Google Patents
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法 Download PDFInfo
- Publication number
- CN109999175A CN109999175A CN201910283674.XA CN201910283674A CN109999175A CN 109999175 A CN109999175 A CN 109999175A CN 201910283674 A CN201910283674 A CN 201910283674A CN 109999175 A CN109999175 A CN 109999175A
- Authority
- CN
- China
- Prior art keywords
- extract
- acne
- compound formulation
- eliminating
- ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 38
- 206010000496 acne Diseases 0.000 title claims abstract description 38
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 33
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 33
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000009472 formulation Methods 0.000 title claims abstract description 30
- 206010000269 abscess Diseases 0.000 title claims abstract description 29
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000284 extract Substances 0.000 claims abstract description 54
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 30
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241001598107 Imperata Species 0.000 claims abstract description 24
- 235000021028 berry Nutrition 0.000 claims abstract description 24
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 21
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 21
- 235000013717 Houttuynia Nutrition 0.000 claims abstract description 20
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 19
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 19
- 244000146462 Centella asiatica Species 0.000 claims abstract description 18
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 18
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 16
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 16
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 16
- 239000012153 distilled water Substances 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 16
- 239000011719 vitamin A Substances 0.000 claims abstract description 16
- 229940045997 vitamin a Drugs 0.000 claims abstract description 16
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 15
- 240000009023 Myrrhis odorata Species 0.000 claims abstract description 14
- 240000000691 Houttuynia cordata Species 0.000 claims abstract 3
- 241000758769 Houttuynia Species 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 240000007311 Commiphora myrrha Species 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 241000205585 Aquilegia canadensis Species 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 206010039083 rhinitis Diseases 0.000 abstract description 8
- 208000020670 canker sore Diseases 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract description 4
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 241000219000 Populus Species 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010060976 Bacillus infection Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 240000000203 Salix gracilistyla Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法，由以下重量份的原料组成：水杨酸：0.001‑0.005mg；左旋Vc：2‑15g；鱼腥草提取物：2‑10g；金银花提取物：3‑16g；柠檬酸：10‑30g；维生素A：10‑30g；茅岩莓提取物：2‑26g；马齿笕提取物：2‑30g；纳米银溶液：0.002‑0.009mg；没药：5‑35g；寡肽‑1：0.02‑0.09mg；积雪草提取物：0.03‑0.09g；蒸馏水：750‑1000g。本发明的复合制剂通过纳米银、水杨酸、茅岩莓、马齿笕鳌合多种消炎杀菌成分，消除暗疮脓肿、皮炎感染、粉刺溃疡，有机复合多种有效成分配方，将其功效提高到鳌合前的数倍，对皮炎感染、粉刺暗疮、口腔溃疡、鼻炎均具良好的改善消除作用，同时该复合制剂原料获取容易，制备简单，具有操作简单、便于应用、疗效显著的优点。
Description
技术领域
本发明涉及水液制剂技术领域，特别是涉及一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法。
背景技术
目前，由于环境污染，饮食不当，精神压力等因素造成人体过氧化，体内自由基大量堆积，内在表现为体内氧化中毒，氧化燃烧形成炎症感染，溃疡脓肿，其机理为：红肿炎症感染溃疡发生时，由于中性粒细胞和巨噬细胞释放大量的自由基（·OH、·O2等），被称为“呼吸爆发”或“氧化燃烧”，结果是自由基破坏正常的组织细胞结构引起局部红肿炎症感染发生，如粉刺暗疮发生过程中，“氧化燃烧”自由基对正常皮肤细胞细胞的破坏作用引起***细胞变异、粉刺杆菌感染发炎。外在表现多为；暗疮脓肿、皮炎感染、粉刺溃疡。例如；粉刺暗疮、口腔溃疡、鼻炎等症状普遍存在。
目前市面上并没有消除暗疮脓肿皮炎感染粉刺溃疡的专用药剂，很多都是通过黄瓜汁、白醋等混合后洗脸和搓脸来进行治疗的，再有就是通过输液或者长期服用具有消炎作用的西药来治疗暗疮、痘痘。这些方法都效果差，不能完全根治。
发明内容
本发明的目的就在于为了解决上述问题而提供一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，利用纳米银、水杨酸、鱼腥草、茅岩莓、柠檬酸等植物提取物强有力消除炎症感染，灭菌消肿功能再加上其它植物成分复合配方来达到治疗暗疮脓肿、皮炎感染、粉刺溃疡的目的。
本发明通过以下技术方案来实现上述目的：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.001-0.005mg；左旋Vc：2-15g；鱼腥草提取物：2-10g；金银花提取物：3-16g；柠檬酸：10-30g；维生素A：10-30g；茅岩莓提取物：2-26g；马齿笕提取物：2-30g；纳米银溶液：0.002-0.009mg；没药：5-35g；寡肽-1：0.02-0.09mg；积雪草提取物：0.03-0.09g；蒸馏水：750-1000g。
进一步的，它主要由如下最佳重量份配比的原材料组成：水杨酸：0.002mg；左旋Vc：8g；鱼腥草提取物：6g；金银花提取物：9g；柠檬酸：10g；维生素A：20g；茅岩莓提取物：3g；马齿笕提取物：10g；纳米银溶液：0.006mg；没药：10g；寡肽-1：0.06mg；积雪草提取物：0.03g；蒸馏水：800g。
进一步的，没药使用前经过研磨处理，得到粉末状药粉。
本发明还提供一种用于制备上述用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂的制备方法，包括如下步骤：
（1）按上述配方重量计，取水杨酸、鱼腥草提取物、马齿笕提取物、茅岩莓、柠檬酸及蒸馏水混合，并加热至85℃，保温搅拌15分钟、以15转/分钟的转速搅拌，得A相溶液；
（2）按上述配方重量计，取金银花提取物、纳米银溶液、寡肽-1、积雪草提取物、没药、维生素A、左旋Vc混合，均质7分钟后，加热至55℃得B相溶液；
（3）得到上述B相溶液后保温并以45转/分钟的搅拌速度搅拌，在搅拌下将上述A相溶液滴入到上述B相溶液中，搅拌均匀后过滤和冷却，冷却完全后制成水液剂；
（4）在无菌条件下将上述水液剂进行灌装和包装储存。
进一步的，所述步骤（3）中搅拌时间为30-45min。
本发明中的药材纯度要求：
水杨酸有效成分纯度99%，左旋Vc有效纯度99%，鱼腥草提取物有效成分纯度98%，金银花提取物有效成分纯度90%，柠檬酸有效成分纯度98%，维生素A有效成分纯度98%，茅岩莓提取物有效纯度98%，马齿笕提取物有效成分纯度90％，纳米银溶液有效成分纯度98%，没药有效成分纯度98%，寡肽-1有效成分纯度99%；积雪草提取物有效成分纯度90%。
本发明的药材功效解析如下：
鱼腥草：味辛，微寒；归肺经；功能与主治：清热解毒，消痈排脓，利尿通淋；用于肺痈吐脓，痰热喘咳，热痢，热淋，痈肿疮毒；
金银花：味甘、性寒；归肺、心、胃经，功用主治：清热，解毒；治温病发热，热毒血痢，痈疡，肿毒，瘰疬，痔漏；
马齿笕：性寒，味甘酸；入心、肝、脾、大肠经；功效主治：清热解毒，利水去湿，散血消肿，除尘杀菌，消炎止痛，止血凉血；主治痢疾，肠炎，肾炎，产后子宫出血，便血，乳腺炎等病症；
没药：味苦辛，性平，无毒，入十二经，功用主治：散血去瘀，消肿定痛；治跌损，金疮，筋骨，心腹诸痛，癥瘕，闭经，痈疽肿痛，痔漏，目障；
积雪草：味苦、辛，性寒；归肝、脾、肾经；功能与主治：清热利湿，解毒消肿：用于湿热黄疸，中暑腹泻，砂淋血淋，痈肿疮毒，跌扑损伤；
本发明中其他原料功效解析如下：
纳米银：纳米银外用一种广谱抗菌物质，能够缓释放出纳米银抑制并杀灭与之接触的病菌，包括痤疮丙酸杆菌、糠秕孢子菌、表皮葡萄球菌，并有促进皮肤愈合的作用；
水杨酸：水杨酸抗茵诈用强、抗菌谱广，水杨酸对常见细菌具有显著的抗菌作用，水扬酸对格兰氏阳性菌、格曼氏阴性菌耐黄色葡萄球菌均有灭活作用；
茅岩莓：茅岩莓具有很强的抗菌消炎作用减少炎性细胞的参与、活化血液中红细胞，增加血红蛋白的含量，提高氧的利用率，减轻各种慢性炎症，茅岩莓通过对杆菌有灭活作用，消除口腔粘膜的炎症，促进鼻炎粘膜溃疡愈合；
寡肽-1：防粉刺、祛疤痕，由于EGF能刺激肉芽组织的形成和促进肉芽组织的上皮化，还可调节胶原降解及更新，使胶原纤维以线性方式排列，防止***异常增生，故而有缩短创伤愈合时间以及减少疤痕形成的作用，对防止痤疮的形成有很好的效果；
左旋Vc：促进骨胶原的生物合成，利于组织创伤口的更快愈合，促进牙齿和骨骼的生长，防止牙床出血，防止关节痛、腰腿痛；增强肌体对外界环境的抗应激能力和免疫力；维生素C，可使皮肤黑色素沉着减少，从而减少黑斑和雀斑，使皮肤白皙；
维生素A：有抗呼吸***感染作用；有助于免疫***功能正常；能保持组织或器官表层的健康；有助于祛除老年斑；外用有助于对粉刺、脓包、疖疮，皮肤表面溃疡等症的治疗；
本发明的有益效果在于：本发明的复合制剂通过纳米银、水杨酸、茅岩莓、马齿笕鳌合多种消炎杀菌成分，消除暗疮脓肿、皮炎感染、粉刺溃疡，有机复合多种有效成分配方，将其功效提高到鳌合前的数倍，对皮炎感染、粉刺暗疮、口腔溃疡、鼻炎均具良好的改善消除作用，同时该复合制剂原料获取容易，制备简单，具有操作简单、便于应用、疗效显著的优点。
具体实施方式
下面将结合实施例对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例一：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.002mg；左旋Vc：8g；鱼腥草提取物：6g；金银花提取物：9g；柠檬酸：10g；维生素A：20g；茅岩莓提取物：3g；马齿笕提取物：10g；纳米银溶液：0.006mg；没药：10g；寡肽-1：0.06mg；积雪草提取物：0.03g；蒸馏水：800g。
实施例二：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.001mg；左旋Vc：2g；鱼腥草提取物：10g；金银花提取物：5g；柠檬酸：15g；维生素A：15g；茅岩莓提取物：8g；马齿笕提取物：29g；纳米银溶液：0.005mg；没药：18g；寡肽-1：0.02mg；积雪草提取物：0.08g；蒸馏水：750g。
实施例三：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.003mg；左旋Vc：15g；鱼腥草提取物：15g；金银花提取物：15g；柠檬酸：25g；维生素A：28g；茅岩莓提取物：9g；马齿笕提取物：15g；纳米银溶液：0.006mg；没药：22g；寡肽-1：0.09mg；积雪草提取物：0.07g；蒸馏水：800g。
实施例四：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.002mg；左旋Vc：4g；鱼腥草提取物：5g；金银花提取物：12g；柠檬酸：26g；维生素A：19g；茅岩莓提取物：6g；马齿笕提取物：20g；纳米银溶液：0.002mg；没药：16g；寡肽-1：0.07mg；积雪草提取物：0.09g；蒸馏水：870g。
实施例五：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.004mg；左旋Vc：10g；鱼腥草提取物：25g；金银花提取物：8g；柠檬酸：18g；维生素A：25g；茅岩莓提取物：10g；马齿笕提取物：18g；纳米银溶液：0.003mg；没药：12g；寡肽-1：0.03mg；积雪草提取物：0.06g；蒸馏水：895g。
实施例六：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.005mg；左旋Vc：11g；鱼腥草提取物：20g；金银花提取物：8g；柠檬酸：30g；维生素A：30g；茅岩莓提取物：7g；马齿笕提取物：25；纳米银溶液：0.009mg；没药：25g；寡肽-1：0.08mg；积雪草提取物：0.04g；蒸馏水：950g。
实施例七：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.001mg；左旋Vc：10g；鱼腥草提取物：8g；金银花提取物：10g；柠檬酸：28g；维生素A：10g；茅岩莓提取物：15g；马齿笕提取物：8g；纳米银溶液：0.007mg；没药：15g；寡肽-1：0.05mg；积雪草提取物：0.05g；蒸馏水：900g。
实施例八：
一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，由以下重量份的原料组成：水杨酸：0.003mg；左旋Vc：9g；鱼腥草提取物：26g；金银花提取物：13g；柠檬酸：22g；维生素A：20g；茅岩莓提取物：16g；马齿笕提取物：13g；纳米银溶液：0.005mg；没药：30g；寡肽-1：0.04mg；积雪草提取物：0.06g；蒸馏水：850g。
本发明还提供一种用于制备上述用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂的制备方法，包括如下步骤：
（1）按上述配方重量计，取水杨酸、鱼腥草提取物、马齿笕提取物、茅岩莓、柠檬酸及蒸馏水混合，并加热至85℃，保温搅拌15分钟、以15转/分钟的转速搅拌，得A相溶液；
（2）按上述配方重量计，取金银花提取物、纳米银溶液、寡肽-1、积雪草提取物、没药、维生素A、左旋Vc混合，均质7分钟后，加热至55℃得B相溶液；
（3）得到上述B相溶液后保温并以45转/分钟的搅拌速度搅拌，在搅拌下将上述A相溶液滴入到上述B相溶液中，搅拌均匀后过滤和冷却，冷却完全后制成水液剂；
（4）在无菌条件下将上述水液剂进行灌装和包装储存。
进一步的，所述步骤（3）中搅拌时间为30-45min。
本发明中的药材纯度要求：
水杨酸有效成分纯度99%，左旋Vc有效纯度99%，鱼腥草提取物有效成分纯度98%，金银花提取物有效成分纯度90%，柠檬酸有效成分纯度98%，维生素A有效成分纯度98%，茅岩莓提取物有效纯度98%，马齿笕提取物有效成分纯度90％，纳米银溶液有效成分纯度98%，没药有效成分纯度98%，寡肽-1有效成分纯度99%；积雪草提取物有效成分纯度90%。
以下为使用本发明复合制剂的临床例子：
1：刘某某，男，19岁，脸部有中度粉刺暗疮，使用本制剂一星期后有明显效果，两星期后脸上粉刺全部消失。
2：王某某，女，38岁，有中度鼻炎脓肿，使用本制剂两星期后，鼻出血现象消失，一个月后，脓肿消失，鼻腔通透。
3：杨某，男，53岁，口腔溃疡一个星期没见好，使用本制剂后1天疼痛感觉消失，3天后痊愈。
选取粉刺暗疮、口腔溃疡、鼻炎皮疹患者各三十名进行临床实验，实验效果如下：
| 种类 | 病例人数 | 观察时间 | 有效治疗 | 完全治愈 | 无效 |
| 粉刺暗疮 | 30 | 15天 | 3 | 27 | 0 |
| 口腔溃疡 | 30 | 4天 | 2 | 28 | 0 |
| 鼻炎皮疹 | 30 | 30天 | 5 | 24 | 1 |
经初步统计，在对消除暗疮粉刺、口腔溃疡、鼻炎皮疹效果良好，有效率达到90%以上；同时使用本发明对皮肤止痒消炎伤口感染等也有很好的愈合作用，有效率达到80%以上。
以上显示和描述了本发明的基本原理、主要特征和优点。本行业的技术人员应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改进都落入要求保护的本发明范围内。
Claims (5)
1.一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，其特征在于：由以下重量份的原料组成：水杨酸：0.001-0.005mg；左旋Vc：2-15g；鱼腥草提取物：2-10g；金银花提取物：3-16g；柠檬酸：10-30g；维生素A：10-30g；茅岩莓提取物：2-26g；马齿笕提取物：2-30g；纳米银溶液：0.002-0.009mg；没药：5-35g；寡肽-1：0.02-0.09mg；积雪草提取物：0.03-0.09g；蒸馏水：750-1000g。
2.根据权利要求1所述的一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，其特征在于：它主要由如下最佳重量份配比的原材料组成：水杨酸：0.002mg；左旋Vc：8g；鱼腥草提取物：6g；金银花提取物：9g；柠檬酸：10g；维生素A：20g；茅岩莓提取物：3g；马齿笕提取物：10g；纳米银溶液：0.006mg；没药：10g；寡肽-1：0.06mg；积雪草提取物：0.03g；蒸馏水：800g。
3.根据权利要求1所述的一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂，其特征在于：没药使用前经过研磨处理，得到粉末状药粉。
4.制备权利要求1或2所述的用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂的制备方法，其特征在于：包括如下步骤：
按上述配方重量计，取水杨酸、鱼腥草提取物、马齿笕提取物、茅岩莓、柠檬酸及蒸馏水混合，并加热至85℃，保温搅拌15分钟、以15转/分钟的转速搅拌，得A相溶液；
按上述配方重量计，取金银花提取物、纳米银溶液、寡肽-1、积雪草提取物、没药、维生素A、左旋Vc混合，均质7分钟后，加热至55℃得B相溶液；
得到上述B相溶液后保温并以45转/分钟的搅拌速度搅拌，在搅拌下将上述A相溶液滴入到上述B相溶液中，搅拌均匀后过滤和冷却，冷却完全后制成水液剂；
在无菌条件下将上述水液剂进行灌装和包装储存。
5.根据权利要求4所述的一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂的制备方法，其特征在于：所述步骤（3）中搅拌时间为30-45min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910283674.XA CN109999175A (zh) | 2019-04-10 | 2019-04-10 | 一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910283674.XA CN109999175A (zh) | 2019-04-10 | 2019-04-10 | 一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109999175A true CN109999175A (zh) | 2019-07-12 |
Family
ID=67170696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910283674.XA Pending CN109999175A (zh) | 2019-04-10 | 2019-04-10 | 一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109999175A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097842A (ja) * | 1999-09-28 | 2001-04-10 | Ichimaru Pharcos Co Ltd | 天然物由来ニキビ治療剤。 |
| CN101249061A (zh) * | 2008-03-17 | 2008-08-27 | 孙和平 | 一种用于解毒消炎的霜剂及其制备方法 |
| US20090068128A1 (en) * | 2007-09-10 | 2009-03-12 | Waddington Tauna A | Scar and rosacea and other skin care treatment composition and method |
| WO2012129683A1 (en) * | 2011-03-25 | 2012-10-04 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of skin disorders |
| CN104971161A (zh) * | 2014-04-02 | 2015-10-14 | 谢天培 | 藤茶提取物的痤疮治疗用途 |
| CN109125151A (zh) * | 2017-06-16 | 2019-01-04 | 广州康其美业生物科技有限公司 | 一种微肽修复面膜精华液 |
-
2019
- 2019-04-10 CN CN201910283674.XA patent/CN109999175A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001097842A (ja) * | 1999-09-28 | 2001-04-10 | Ichimaru Pharcos Co Ltd | 天然物由来ニキビ治療剤。 |
| US20090068128A1 (en) * | 2007-09-10 | 2009-03-12 | Waddington Tauna A | Scar and rosacea and other skin care treatment composition and method |
| CN101249061A (zh) * | 2008-03-17 | 2008-08-27 | 孙和平 | 一种用于解毒消炎的霜剂及其制备方法 |
| WO2012129683A1 (en) * | 2011-03-25 | 2012-10-04 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of skin disorders |
| CN104971161A (zh) * | 2014-04-02 | 2015-10-14 | 谢天培 | 藤茶提取物的痤疮治疗用途 |
| CN109125151A (zh) * | 2017-06-16 | 2019-01-04 | 广州康其美业生物科技有限公司 | 一种微肽修复面膜精华液 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230493B (zh) | 一种治疗创口不愈的中药组合物 | |
| CN105012392A (zh) | 一种用于治疗鼻炎的中药组合物及其制备方法 | |
| CN103520348B (zh) | 治疗痔疮的外用中药药油 | |
| CN110652544A (zh) | 一种治疗鼻炎的药物组合物及其制备方法 | |
| CN105194364A (zh) | 一种用于局部烧伤护理的药物组合物 | |
| CN104825905A (zh) | 一种治疗输血反应的中药制剂及其制备方法 | |
| CN108066224A (zh) | 一种安胃疡牙膏及其制备方法 | |
| CN108057115A (zh) | 一种治疗上呼吸道炎症感染的组合物及其制备方法 | |
| CN109999175A (zh) | 一种用于消除暗疮脓肿皮炎感染粉刺溃疡的复合制剂及其制备方法 | |
| CN104491825B (zh) | 一种治疗口腔溃疡的中药药膏 | |
| CN105106096A (zh) | 一种口腔护理液 | |
| CN104922449A (zh) | 一种中药消毒液及其制备方法 | |
| CN104173973A (zh) | 一种治疗痢疾的口服液及其制备方法 | |
| CN104587035B (zh) | 一种治疗口腔溃疡的药物组合物及其制备方法 | |
| CN103181964B (zh) | 治疗动物体表创伤的中药组合物及其制备方法 | |
| CN108114220A (zh) | 一种治疗鼻炎的胶囊剂药物及制备方法 | |
| CN110227109B (zh) | 一种用于猪慢性湿疹的组合物及其制备方法 | |
| CN107468870A (zh) | 一种用于治疗皮炎的软膏剂药物及其制备方法 | |
| CN108420952A (zh) | 消炎解毒利尿汤 | |
| CN107617009B (zh) | 一种治疗家兔皮肤毛囊炎的复方中草药外用制剂 | |
| CN105326943A (zh) | 一种治痔疮的纯中药 | |
| CN104940285A (zh) | 一种医用生物咽喉肿痛修复敷料及其制备方法 | |
| CN105194289B (zh) | 一种治疗皮肤病的外用药物及其制备方法 | |
| CN104623420B (zh) | 一种治疗扁平疣的中药软膏 | |
| CN113616707A (zh) | 一种基于3d打印并用于创伤治疗的制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190712 |
|
| RJ01 | Rejection of invention patent application after publication |